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Purpose: Systemic inﬂammatory conditions, as seen in obesity and in the metabolic syndrome, are asso-
ciated with high plasmatic levels of proatherogenic and prothromboticadipokines and low levels of
adiponectin. Inhibitors of HMG-CoA reductase have beneﬁcial effects in reducing cardiovascular events
attributed predominantly to its lipid-lowering effects and recent studies suggest that these effects might
be due to its anti-inﬂammatory properties. Based on the pleiotropic properties of simvastatin we studied
the effects of this drug on the secretion and expression of adiponectin, PAI-1 and MCP-1 in mature adi-
pocytes under baseline conditions and after an inﬂammatory stimulation.
Materials and methods: The differentiated adipocytes were incubated with 10 lM simvastatin or vehicle
and TNF-a 10 ng/mL or vehicle were added to treatment media. After 24 h of incubation, the media was
harvested and the proteins of interest were analyzed by Multiplex method. Gene expression was ana-
lyzed by real time-PCR.
Results: The addition of TNF-a increased the expression and secretion of MCP-1 and PAI-1. However,
stimulation did not interfere with the secretion of adiponectin, despite having signiﬁcantly reduced its
expression. Our data also demonstrated that simvastatin reduced the expression and secretion of MCP-
1, under baseline (770.4 ± 199.9 vs 312.7 ± 113.7 and 1.00 ± 0.14 vs 0.63 ± 0.13, p < 0.05, respectively)
and inﬂammatory conditions (14945 ± 228.7 vs 7837.6 ± 847.4 and 24.16 ± 5.49 vs 14.97 ± 2.67,
p < 0.05, p < 0.05, respectively). Simvastatin also attenuated the increase in expression and secretion of
PAI-1 induced by TNF-a (16898.6 ± 1663.3 vs 12922.1 ± 843.9 and 5.19 ± 3.12 vs 0.59 ± 0.16, respectively
p < 0.05), but under baseline conditions had no effect on the expression or secretion of PAI-1. The statin
increased the expression of adiponectin under baseline conditions and inﬂammatory stimulation
(1.03 ± 0.08 vs 4.0 ± 0.96 and 0.77 ± 0.19 vs 2.16 ± 0.23, respectively, p < 0.05) and also increased the
secretion of this adipokine but only with the inﬂammatory stimulus (5347.7 ± 1789.3 vs
7327.3 ± 753.6, p < 0.05).
Conclusions: Our ﬁndings suggested that simvastatin counteracted the stimulatory effect of TNF-a on
secretion and expression of MCP-1, PAI-1 and adiponectin, implying a potential anti-atherogenic effect
during the inﬂammatory process; these pleitropic effects were more pronounced with HMG-CoA reduc-
tase inhibitor.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Atherosclerosis is one of the principal causes of mortality in the
world. Inﬂammation, the physiopathologic basis of atherosclerosis,
is not included among the classic risk factors but does appear to be
an additional important therapeutic target in the reduction of car-
diovascular risk [1,2].Toledo, 781, 14 andar CEP
6x26; fax: +55 11 55739652.
o).
ier OA license.The increase in the secretion of biologically active molecules
such as MCP-1 (monocyte chemoattractant protein-1) [3–5] and
PAI-1 (plasminogen activator inhibitor-1) [6–8] has an ominous
impact on the progression of atherogenesis. In contrast, adiponec-
tin, the most abundant gene product of adipocytes, has a protective
effect against the development of atherosclerotic disease, and its
levels are reduced in metabolic syndrome [9,10].
The implication of drugs used primarily for treatment of dysli-
pidemia in pleiotropic and anti-atherogenic actions [11,12], addi-
tionally to modifying effects on the lipid proﬁle, has been the
focus of more recent studies and can lead to a therapeutic
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risk [13,14]. Ridker et al. demonstrated that the use of rosuvastatin,
a HMG-CoA reductase inhibitor, leads to a signiﬁcant decrease in
coronary risk in non-dyslipidemic individuals with elevated C reac-
tive protein, a marker of systemic inﬂammation [15].
The objective of this study was to investigate the ‘‘in vitro’’ ef-
fect of simvastatin on the secretion and expression of adiponectin,
PAI-1 and MCP-1 in mature adipocytes derived from the 3T3-L1
cell line, under baseline conditions and after an inﬂammatory
stimulation, mimicking the inﬂammatory milieu of metabolic
syndrome.Fig. 1. Effect of DMSO on adiponectin secretion.2. Methods
2.1. Cell culture
Murine ﬁbroblasts of the immortalized cell line 3T3-L1, in the
11th passage were stored in liquid nitrogen, at -120 C until
thawed, plated and grown in DMEM-HG (Dulbecco’s Modiﬁed Eagle
Medium high glucose, Gibco) culture medium supplemented with
10% fetal bovine serum (10% FBS, Gibco). On reaching conﬂuence,
the cells were harvested after trypsinization and distributed into
6-well plates. The ﬁbroblasts, then in their 12th passage, were
grown to 90% conﬂuence, at which time differentiation into adipo-
cytes step then initiated, according to a previously established pro-
tocol [16]. In order to induce 3T3-L1 cells to differentiate into
adipocytes, on the 1st day (D0), the culture medium was substi-
tuted with DMEM HGmedium containing 10% FBS, 160 nM insulin,
250 lM dexamethasone and 0.4 mM 3-isobutyl 1-methylxanthine
(IBMX, Sigma) (differentiation medium). On D4, after 96 h of incu-
bation, differentiation medium was substituted with DMEM HG
medium containing 160 nM insulin and 10% of FBS (feeding med-
ium). After 72 h (D7), the latter medium was refreshed, and at
D10, the cells differentiated into adipocytes were incubated for
24 h in culture medium containing simvastatin (treatment med-
ium) or culture medium without drug (control medium). TNF-a
(Sigma), used to mimic the inﬂammatory state at the ﬁnal concen-
tration of 10 ng/mL [16] was added with the treatment medium or
the control medium in 2 of the 6-well cell culture plates. Previ-
ously, adipocytes were incubated with TNF-a (1, 10, 25 and
50 ng/mL) and we veriﬁed that at 25 and 50 ng/mL of TNF- a, the
concentration of adiponectin in medium decreased, but generated
a decrease of 35% in cell viability. During the whole process, the
cells were kept in at 37 C incubator, at 5% CO2 and at ideal humid-
ity conditions.Fig. 2. Dose-response effect of simvastatin on MCP-1 and PAI-1 adipocyte’s release.2.2. Treatment
On the 10th day after the start of differentiation, the culture
medium in the wells was replaced with medium containing simva-
statin (Sigma), vehicle (non-supplemented DMEM HG medium),
simvastatin + TNF-a and TNF-a only. Each of the 6-well plates
was considered a distinct treatment group (n = 6). The medium
without drug and without stimulus was considered the baseline
control; the medium without drug and with added TNF-a (10 ng/
mL) was called the control with stimulus.
Previously, simvastatin was diluted and activated as followed:
in a 1.5-mL tube, 5 mg simvastatin (Sigma) were dissolved in
190 lL DMSO and 810 lL Milli-Q water. NaOH, 0.1 M, was added
to the tube, which was then heated at 70 C for 2 h [17]. This solu-
tion was serially diluted with DMEM medium, in order to obtain a
medium with 10 lM simvastatin.
After serial dilutions to reach the ﬁnal work concentration of
10 lM simvastatin the ﬁnal percentage of DMSO was less than
0.002%.A control assay was performed to verify the inﬂuence of DMSO
at 0.002% on adiponectin production after 6, 24 and 30 h of incuba-
tion (Fig. 1).
2.3. Dose effects of simvastatin on MCP-1 and PAI-1 release by
adipocytes
To choose optimal simvastatin concentration on adipokines re-
lease by adipocytes, cells (N = 4) were incubated with increasing
doses of simvastatin (0.1, 10, 100 lM) for 24 h. Concentrations of
MCP-1 and PAI-1 were determined in the 24 h culture superna-
tants of adipocytes. In this preliminary protocol, our results sug-
gest that simvastatin had no dose-dependent effect (Fig. 2) and,
therefore, 10 lM concentration was chosen to carry out the study.
Under TNF-a stimulating condition simvastatin either had no
dose-dependent effect (data not shown).
Based on a pilot time-response experiment (12, 24, 30 h) were
adipocytes raised maximum production of MCP-1 and PAI-1 after
24 h of incubation with TNF-a; all assays were carried out during
this period (data not shown).
2.4. Characterization of differentiation of ﬁbroblasts into adipocytes by
oil red staining
On D4, the ﬁbroblasts began to acquire the phenotype of adipo-
cytes, with accumulation of fat droplets in the cytoplasm. On D10,
about 70% of the ﬁbroblasts had differentiated into adipocytes.
The formation of lipid droplets, a morphologic appearance charac-
teristic of adipocytes, was conﬁrmed by oil red (Sigma) staining.
The process of the differentiation of 3T3-L1 ﬁbroblasts into adipo-
152 S.M.V. Lobo et al. / Cytokine 60 (2012) 150–156cytes was evaluated every 24 h starting at D0, by observing the
morphologic appearance of the cells with a light microscope. Adi-
pocytes were identiﬁed by oil red staining of lipid droplets which
are characteristically found in the cytoplasm of adipocytes [18].
Initially, 60 mg of oil red stain were dissolved in 20 mL of isopropa-
nol. Next, 300 lL of this solution were diluted in water in 6:4 pro-
portions. Culture medium was aspirated and the wells were
washed twice with phosphate-buffered saline (PBS). Next, 4% para-
formaldehyde (diluted in PBS), was added in a volume sufﬁcient to
cover the cells. After 30 min at room temperature, the mediumwas
aspirated and the wells were washed 3 times with PBS. The cells
were then incubated in oil red solution (300 lL) for 2 h, at 37 C.
Afterward, the medium was aspirated, and the plates were washed
thrice with distilled water and placed into the incubator, at 37 C to
dry. After this step, the cells were examined with optic microscope
and photographs were taken.
2.5. Determination of cell viability
We could observe by trypan blue (Sigma) exclusion that from
the 4th to the 10th day, at the beginning of differentiation, cell via-
bility was about 95% (data not shown). The cells were trypsinized
and suspended in 10 mL of PBS. A 25-lL aliquot of this cell suspen-
sion was mixed with 75 lL trypan blue stain. From this mixture,
10 lL were placed in a Neubauer chamber to count viable nucleus
cells stained in red.
2.6. Analysis of the secretion of MCP-1, PAI-1 and adiponectin by
adipocytes
The secretion of the adipokines was determined by the quanti-
ﬁcation of the concentrations of MCP-1, PAI-1 and adiponectin in
the cell culture medium, using the Luminex xMAP method, with
the multiplex Mouse Adipocyte Panel kit (Linco, Millipore), and
according to the manufacturers’ instructions. MCP-1 and PAI-1
were assayed simultaneously. The quantiﬁcation of adiponectin
was done separately, after the samples had been diluted 500 times
in DMEM medium.
2.7. Gene expression and secretion of proteins of interest
The primers for the proteins of interest were designed using the
Primer Express program (Applied Biosystems, USA), based on
gene sequences obtained at GenBank. Each pair was analyzed uti-
lizing nucleotide-nucleotide Blast (available at http://
www.ncbi.nlm.nih.gov/ BLAST/). Total RNA was extracted from
the cultured adipocytes with the QuantiTect kit (Qiagen), in accor-
dance with the manufacturer’s instructions. Next, cDNA was pre-
pared using 1 lg total RNA and the appropriate kit (RT-PCR kit,
GLT). An aliquot of cDNA was mixed with the speciﬁc primers for
the genes of interest, along with deoxynucleotides, Taq polymeraseTable 1
Effect of TNF-a stimulus on the secretion and expression of MCP-1, PAI-1 and Adiponectin
Spontaneous Simvastatin co
Secretion (pg/mL)
MCP-1 770.4 ± 199.9 312.7 ± 113.7*
PAI-1 14371 ± 1011 17538.9 ± 1538
Adiponectin (x103) 5643 ± 121.2 6801 ± 533.2
Relative mRNA expression
MCP-1 1.0 ± 0.14 0.63 ± 0.13*
PAI-1 0.93 ± 0.12 1.06 ± 0.09
Adiponectin 1.03 ± 0.08 4.0 ± 0.96*
* Spontaneous vs Simvastatin control, p < 0.05.
** TNF- a stimulus vs Simvastatin + TNF-a, p < 0.05.and the ﬂuorescent stain SybrGreen, (Quantitect kit, Qiagen). Real-
time quantitative PCR was performed in a thermocycler (ABI 7700).
The speciﬁcity of the product was conﬁrmed by melting point
curve analysis, as well as by conventional agarose gel electropho-
resis. The products were quantiﬁed and compared to controls
based on the analysis of the number cycles necessary to obtain a
given ﬂuorescence value in the log-linear phase of the reaction.
Reactions utilizing the primer for the housekeeping gene HPRT
were systematically performed, and all values obtained for the
genes of interest were normalized with HPRT expression.
2.8. Statistical analysis
The statistical analyses were performed using the software SPSS
16.0. The results for each individual group were expressed as a
mean ± standard deviation. The t-test for independent samples
was used for comparison between baseline control and control
after TNF-a. Statistical signiﬁcance of differences between the vari-
ables studied was determined by analysis of variance (ANOVA),
complemented by Bonferroni’s test. In all tests, the level of statis-
tical signiﬁcance considered was 0.05.
3. Results
3.1. Effect of TNF-a on the expression and secretion of the adipokines
The cells incubated with TNF-a increased the expression and
secretion of MCP-1 by adipocytes approximately 19 and 24 times,
respectively. The inﬂammatory stimulus also induced an increase
in the expression and secretion of PAI-1. Unlike what was observed
in the experiments with other adipokines, there was no difference
between the concentrations in culture medium of 3T3-L1 cells for
adiponectin under baseline conditions or TNF-a stimulus. How-
ever, TNF-a signiﬁcantly decreased the expression of adiponectin.
There was a correlation between the expression and secretion of
MCP-1 (r = 0.93; p < 0.001) and of PAI-1 (r = 0.64; p < 0.001), but
not between expression and secretion of adiponectin.
3.2. Effect of simvastatin on MCP-1
In the adipocytes, simvastatin induced a statistically signiﬁcant
decrease in the secretion as well as expression of MCP-1 under
baseline conditions (770.4 ± 199.9 vs 312.7 ± 113.7 and
1.00 ± 0.14 vs 0.63 ± 0.13, p < 0.05, respectively) and after stimula-
tion with TNF-a (14,945 ± 228,7 vs 7837.6 ± 847.4 and 24.16 ± 5.49
vs 14.97 ± 2.67, p < 0.05, respectively) (Table 1) (Fig. 3).
3.3. Effect of simvastatin on PAI-1
Under baseline conditions, the statin didnot exert an effect on
the expression or secretion of PAI-1. Under inﬂammatory stimulus,.
ntrol TNF-a Stimulus Simvastatin + TNF-a
14945.0 ± 228.7 7837.6 ± 847.4**
16898.6 ± 1663.3 12,922 ± 843.9**
5347.7 ± 1789.3 7327.3 ± 753.6**
24.16 ± 5.49 14.97 ± 2.67**
5.19 ± 3.12 0.59 ± 0.16**
0.77 ± 0.19 2.16 ± 0.23**
Fig. 3. Effects of lipid proﬁle-modifying drugs on secretion (A) and expression (B) of MCP-1 in 3T3-L1 adipocytes (n = 6) under normal condition on left (gray) and under
inﬂammatory stimulation on right (black).
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(16898.6 ± 1663.3 vs 12922.1 ± 843.9 and 5.19 ± 3.12 vs
0.59 ± 0.16, respectively p < 0.05) (Table 1) (Fig. 4).
3.4. Effect of simvastatin on adiponectin
The statin increased the expression of this adipokine under both
baseline conditions and inﬂammatory stimulus (1.03 ± 0.08 vs
4.0 ± 0.96 and 0.77 ± 0.19 vs 2.16 ± 0.23, respectively, p < 0.05)
and increased the secretion of adiponectin only after the inﬂamma-
tory stimulus (5347.7 ± 1789.3 vs 7327.3 ± 753.6, p < 0.05) (Table 1)
(Fig. 5).
4. Discussion
In the present study, we observed that TNF-a, is active in differ-
entiated 3T3-L1 adipocytes, simulating the inﬂammatory millieu of
obesity and metabolic syndrome by increasing the expression and
secretion of MCP-1 and PAI-1. These ﬁndings corroborate the
hypothesis that this tissue is of utmost importance in the perpetu-
ation of the inﬂammatory status and pro-thrombotic effect associ-
ated with inﬂammation. However, TNF-a did not interfere with the
secretion of adiponectin, despite having signiﬁcantly reduced its
expression. The discrepancy between the effects of TNF-a on
adiponectin gene expression and secretion may be due to differ-
ences in the half-life of adiponectin protein in the culture medium,
relative to the half-life of adiponectin mRNA. Additionally, the
measurement of adiponectin secretion was relied upon accumula-
tion of this protein in the culture medium over 24 h and doesnot
account for the rate of degradation following release. This result
concurs with the ﬁnding of Wang et al., who demonstrated that
incubation with TNF-a for 24 h did not alter the secretion of thisadipokine by 3T3-L1 mature adipocytes, even reducing its gene
expression [19].
Our data also demonstrated that simvastatin markedly reduced
the expression and secretion of MCP-1, under baseline and inﬂam-
matory conditions. In fact, Han and coworkers observed that the
use of simvastatin diminished the expression ofMCP-1 in themono-
cytes of normocholesterolemic patients [3]. Inhibitors of 3-hydro-
xy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibits
the synthesis of mevalonic acid [11], and consequently the produc-
tion of intermediate isoprenoids [4,11], which are activators of
intracellular signaling proteins, responsible for the initiation of
inﬂammatory cascades. It is well documented that this effect can
be reversed by the administration of mevalonate [20]. Additionally,
the action of the statin has been relatedwith the inhibition of NF-jB
transcription factor pathway, which is essential in the gene expres-
sion of numerous atherogenic mediators, including MCP-1 [12].
Regarding to PAI-1, the present work showed that simvastatin
only attenuated the increase in the expression and secretion of
PAI-1 induced by TNF-a, an observation contrary to a study by Lau-
men et al., who reported that rosuvastatin was able of decrease the
secretion of PAI-1 by 50% under baseline conditions, in 3T3-L1 adi-
pocytes [17]. Such divergence could be attributed to pharmaco-
logic differences between rosuvastatin and simvastatin. Although
few reported studies related to the action of the HMG-CoA inhibi-
tor on the secretion of PAI-1 by 3T3-L1 adipocytes we suggested
that the statin had a beneﬁcial effect on adipose tissue, since the
drug attenuated the pro-thrombotic state induced by TNF-a. In
fact, our group had already demonstrated that treatment of periph-
eral blood mononuclear cells isolated from critically ill patients
with simvastatin resulted in an attenuation of spontaneous pro-
inﬂammatory cytokine production concurring with potential ben-
eﬁt of statins in this scenario [21].
Fig. 4. Effects of lipid proﬁle-modifying drugs on secretion (A) and expression (B) of PAI-1 in 3T3-L1 adipocytes (n = 6) under normal condition on left (gray) and under
inﬂammatory stimulation on right (black).
Fig. 5. Effects of lipid proﬁle-modifying drugs on secretion (A) and expression (B) of adiponectin in 3T3-L1 adipocytes (n = 6) under normal condition on left (gray) and under
inﬂammatory stimulation on right (black).
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under both baseline and inﬂammatory stimulation, but only in-
creased the secretion of this adipokine with the inﬂammatory
stimulus. It is known that adiponectin is very abundant in the plas-
ma, even under baseline conditions, but mechanisms of stimuli
that act on its secretion have been poorly elucidated. Our data cor-
roborates the study conducted by Sakamoto and coworkers, who
demonstrated that the use of pravastatin (other HMG-CoA reduc-
tase inhibitors) was capable of signiﬁcantly increase the adiponec-
tinemia in dyslipidemic patients [22].
It has been described that TNF-a induce the nuclear transloca-
tion of NF-jB and upregulate the expression and secretion of
MCP-1, PAI-1 and PCR [23]. The simvastatin effect in diminishing
the mRNA expression and secretion of MCP-1, observed in our re-
sults could be attributed to the increased production of adiponec-
tin once it is known that this adipokine inhibits the NF-jB pathway
[24]. Others transcriptions factor have been described to be altered
by statins. KFL4 a member of the Kruppel-like family mediates the
anti-inﬂamatory effects of statins on endothelial cells. In this cells
statins upregulate extracellular signal-regulated kinase (Erk5) by
the MEK5/mitogen activated protein kinase pathway [25]. Birsoy
et al. reported the characterization of KLF4 as an essential early
regulator of adipogenesis. In their work it was demonstrated that
KLF 4 is expressed in 3T3-L1 and knockdown of KLF4 inhibits
adipogenesis, downregulates CCAAT/enhancer-binding protein
(C/EBPbeta) levels, wich then stimulate the expression of PPAR c
[26].Based on the fact that antiatherogenic effects of PPAR agonists
and statins have common characteristics, Yano et al. suggested that
a common mechanism may exist via crosstalk of their pathway
[27,28]. This study demonstrated that statins suppressed LPS-in-
duced expression of TNF-a and MCP-1 and activation of NF-KB
and activator protein-1 (AP-1) through PPARa- and PPARc-depen-
dent pathways. Therefore, statins might suppress inﬂammatory re-
sponses via activation of both PPARa and PPARc, thereby including
antiatherogenic actions [27].
In conclusion our ﬁndings demonstrated simvastatin counter-
acted the stimulatory effect of TNF-a on secretion and expression
of MCP-1, PAI-1 and adiponectin, suggesting a potential anti-ath-
erogenic effect during the inﬂammatory process involved in meta-
bolic syndrome as well as in the progression of atherosclerosis. The
translation of such observations to clinical setting requires further
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